# Efficacy and Safety of Insulin Glargine/Lixisenatide Fixed Combination Versus Insulin Glargine Alone on Top of Metformin in Type 2 Diabetic Patients

> **NCT01476475** · PHASE2 · COMPLETED · sponsor: **Sanofi** · enrollment: 323 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** Insulin glargine /lixisenatide Fixed Ratio Combination
- **DRUG:** Insulin glargine
- **DRUG:** Metformin (Background drug)

## Key facts

- **NCT ID:** NCT01476475
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-11
- **Primary completion:** 2012-12
- **Final completion:** 2012-12
- **Target enrollment:** 323 (ACTUAL)
- **Last updated:** 2017-02-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01476475

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01476475, "Efficacy and Safety of Insulin Glargine/Lixisenatide Fixed Combination Versus Insulin Glargine Alone on Top of Metformin in Type 2 Diabetic Patients". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01476475. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*